

Information pursuant to Sec. 125 (1), (5) AktG in connection with Article 4 (1) and Table 3 of the Annex to Implementing Regulation (EU) 2018/1212 („Implementing Regulation (EU)“)

Type of information	Description
A. Specification of the message	
1. Unique identifier of the event	Virtual Annual General Meeting of SCHOTT Pharma AG & Co. KGaA Specification in accordance with Implementing Regulation (EU): e01bf5777997ef11b53b00505696f23c
2. Type of Message	Convening of the Annual General Meeting Specification in accordance with Implementing Regulation (EU): NEWM
B. Specification of the issuer	
1. ISIN	DE000A3ENQ51
2. Name if the issuer	SCHOTT Pharma AG & Co. KGaA
C. Specification of the meeting	
1. Date of the General Meeting	February 4, 2025 Specification in accordance with Implementing Regulation (EU): 20250204
2. Time of the General Meeting	10:00 (CET) Specification in accordance with Implementing Regulation (EU): 09:00 (UTC)
3. Type of the General Meeting	Annual General Meeting held as a virtual general meeting without the physical presence of shareholders or their representatives (with the exception of the proxies appointed by the Company to exercise voting rights) Specification in accordance with Implementing Regulation (EU): GMET
4. Location of the General Meeting	URL to the Company's InvestorPortal to follow the Annual General Meeting in video and audio and to exercise shareholders' rights: https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/

	<p>Location of the Annual General Meeting in accordance with the German Stock Corporation Act:</p> <p>Erich-Schott-Centrum, room 1.05/studio, Hattenbergstraße 10, 55122 Mainz</p>
5. Record Date	<p>January 13, 2025 (24:00 (CET))</p> <p>Specification in accordance with Implementing Regulation (EU): 20250113, 23:00 (UTC)</p>
6. Uniform Resource Locator (URL)	<p>https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</p>
D. Participation in the general meeting	
1. Method of participation by shareholder	<p>Access and participation by way of electronic communication via the password-protected InvestorPortal under https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/</p> <p>Voting rights exercised by voting by mail</p> <p>Voting rights exercised by authorizing and instructing proxies appointed by the Company (also by a proxy)</p> <p>Specification in accordance with Implementing Regulation (EU): VI, EV, PX</p>
2. Issuer deadline for the notification of participation	<p>January 28, 2025, 24:00 (CET)</p> <p>Specification in accordance with Implementing Regulation (EU): 20250128; 23:00 (UTC)</p>
3. Issuer deadline for voting	<p><u>The exercise of voting rights by way of voting by mail,</u></p> <ul style="list-style-type: none"> via the password-protected InvestorPortal under https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/ until the time determined by the chairman of the meeting in the context of the voting at the Annual General Meeting on February 4, 2025 <p>Specification in accordance with Implementing Regulation (EU): 20250204; until the time determined by the chairman of the meeting in the context of the voting</p> <ul style="list-style-type: none"> by mail or by e-mail or by SWIFT: not later than February 3, 2025, 24:00 (CET). <p>Specification in accordance with Implementing Regulation (EU): 20250203; 23:00 (UTC)</p> <p><u>Exercising voting rights by granting power of attorney and issuing instructions to the proxies appointed by the Company,</u></p> <ul style="list-style-type: none"> via the password-protected InvestorPortal under https://www.schott-pharma.com/investor-

	<p>relations/events/annual-general-meeting/ until the time determined by the chairman of the meeting in the context of the voting at the Annual General Meeting on February 4, 2025</p> <p>Specification in accordance with Implementing Regulation (EU): 20250204; until the time determined by the chairman of the meeting in the context of the voting</p> <ul style="list-style-type: none"> • by mail or by e-mail or by SWIFT: not later than February 3, 2025, 24:00 (CET). <p>Specification in accordance with Implementing Regulation (EU): 20250203; 23:00 (UTC)</p>
E. Agenda	
E. Agenda – Agenda Item 1	
1. Unique identifier of the agenda item	1
2. Title of the agenda item	<p>Presentation of the annual financial statements and consolidated financial statements of SCHOTT Pharma AG & Co. KGaA, each approved by the Supervisory Board, the combined management report for SCHOTT Pharma AG & Co. KGaA and the Group, the explanatory report of the General Partner on the information pursuant to sections 289a and 315a of the German Commercial Code (Handelsgesetzbuch – HGB) and the report of the Supervisory Board of SCHOTT Pharma AG & Co. KGaA, each for fiscal year 2023/2024; resolution on the adoption of the annual financial statements of SCHOTT Pharma AG & Co. KGaA for fiscal year 2023/2024</p>
3. Uniform Resource Locator (URL) of the materials	https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/
4. Vote	<p>Binding Vote</p> <p>Specification in accordance with Implementing Regulation (EU): BV</p>
5. Alternative voting options	<p>Vote in favour; vote against; abstention</p> <p>Specification in accordance with Implementing Regulation (EU): VF, VA, AB</p>
E. Agenda – Agenda Item 2	
1. Unique identifier of the agenda item	2

2. Title of the agenda item	Resolution on the allocation of distributable profit
3. Uniform Resource Locator (URL) of the materials	https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
E. Agenda – Agenda Item 3	
1. Unique identifier of the agenda item	3
2. Title of the agenda item	Resolution on the approval of the actions of the General Partner for fiscal year 2023/2024
3. Uniform Resource Locator (URL) of the materials	https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
E. Agenda – Agenda Item 4	
1. Unique identifier of the agenda item	4
2. Title of the agenda item	Resolution on the approval of the actions of the Supervisory Board for fiscal year 2023/2024
3. Uniform Resource Locator (URL) of the materials	https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV

5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
E. Agenda – Agenda Item 5	
1. Unique identifier of the agenda item	5
2. Title of the agenda item	Election of the auditor and the Group auditor for fiscal year 2024/2025 as well as the auditor for the potential review of the condensed financial statements and the interim management report for fiscal year 2024/2025 and other interim financial information
3. Uniform Resource Locator (URL) of the materials	https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
E. Agenda – Agenda Item 6	
1. Unique identifier of the agenda item	6
2. Title of the agenda item	Resolution on the approval of the remuneration report for fiscal year 2023/2024
3. Uniform Resource Locator (URL) of the materials	https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/
4. Vote	Advisory Vote Specification in accordance with Implementing Regulation (EU): AV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB

E. Agenda – Agenda Item 7	
1. Unique identifier of the agenda item	7
2. Title of the agenda item	Resolution on the election of a new member of the Supervisory Board
3. Uniform Resource Locator (URL) of the materials	https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
E. Agenda – Agenda Item 8	
1. Unique identifier of the agenda item	8
2. Title of the agenda item	Resolution on the approval of the conclusion of a Profit Transfer Agreement between the Company and SCHOTT Pharma Mexico GmbH
3. Uniform Resource Locator (URL) of the materials	https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/
4. Vote	Binding Vote Specification in accordance with Implementing Regulation (EU): BV
5. Alternative voting options	Vote in favour; vote against; abstention Specification in accordance with Implementing Regulation (EU): VF, VA, AB
F. Specification of the deadlines regarding the exercise of other shareholders rights	
F. Shareholder Right – Requests for amendments to the agenda pursuant to sec. 278 (3), 122 (2) AktG	
1. Object of deadline	Submission of the request for amendments of the agenda
2. Applicable issuer deadline	January 4, 2025, 24:00 (CET)

	Specification in accordance with Implementing Regulation (EU): 20250104; 23:00 (UTC)
F. Shareholder Right – Countermotions pursuant to sec. 278 (3), 126, 118a (1), sentence 2 no. 3, 130a (5) sentence 3 AktG	
1. Object of deadline	Submission of countermotions on specific items on the agenda
2. Applicable issuer deadline	January 20, 2025, 24:00 (CET) Specification in accordance with Implementing Regulation (EU): 20250120; 23:00 (UTC)
F. Shareholder Right – Election proposals pursuant to sec. 278 (3), 127, 118a (1), sentence 2 no. 3, 130a (5) sentence 3 AktG	
1. Object of deadline	Transmission of the election proposal for the election of auditors or for the election of supervisory board members
2. Applicable issuer deadline	January 20, 2025, 24:00 (CET) Specification in accordance with Implementing Regulation (EU): 20250120; 23:00 (UTC)
F. Shareholder Right – Right to submit statements pursuant to sec. 278 (3), 118a (1), sentence 2 no. 6, 130a (1) to (4) AktG	
1. Object of deadline	Submission of statements on agenda items by way of electronic communication via the E-Mail Stellungnahme.Pharma@schott.com
2. Applicable issuer deadline	January 29, 2025, 24:00 (CET) Specification in accordance with Implementing Regulation (EU): 20250129; 23:00 (UTC)
F. Shareholder Right – Right to speak pursuant to sec. 278 (3), 118a (1), sentence 2 no. 7, 130a (5) and (6) AktG	
1. Object of deadline	Right to speak at the Annual General Meeting by way of video communication via the InvestorPortal
2. Applicable issuer deadline	on February 4, 2025 according to the instructions of the chairman of the meeting during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20250204 according to the instructions of the chairman of the meeting during the Annual General Meeting
F. Shareholder Right – Right to propose motions at the Annual General Meeting	
1. Object of deadline	Submitting motions and election proposals by way of video communication via the InvestorPortal
2. Applicable issuer deadline	on February 4, 2025 according to the instructions of the chairman of the meeting during the Annual General Meeting

	Specification in accordance with Implementing Regulation (EU): 20250204 according to the instructions of the chairman of the meeting during the Annual General Meeting
F. Shareholder Right – Right to information pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (1), (1f), (4) and (5), 293g (3) AktG	
1. Object of deadline	Right to obtain information at the Annual General Meeting by way of video communication via the InvestorPortal
2. Applicable issuer deadline	on February 4, 2025 according to the instructions of the chairman of the meeting during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20250204 according to the instructions of the chairman of the meeting during the Annual General Meeting
F. Shareholder Right – Request pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (4) sentence 1, 2 AktG	
1. Object of deadline	Submission of requests pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (4) sentence 1, 2 AktG by way of electronic communication via the InvestorPortal
2. Applicable issuer deadline	on February 4, 2025 according to the instructions of the chairman of the meeting during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20250204 according to the instructions of the chairman of the meeting during the Annual General Meeting
F. Shareholder Right – Requests pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (5) AktG	
1. Object of deadline	Submission of requests pursuant to sec. 278 (3), 118a (1), sentence 2 no. 4, 131 (5) AktG by way of electronic communication via the InvestorPortal
2. Applicable issuer deadline	on February 4, 2025 according to the instructions of the chairman of the meeting during the Annual General Meeting Specification in accordance with Implementing Regulation (EU): 20250204 according to the instructions of the chairman of the meeting during the Annual General Meeting
F. Shareholder Right – Objection to resolutions of the Annual General Meeting	
1. Object of deadline	Filing of objections to resolutions of the Annual General Meeting by way of electronic communication via the InvestorPortal pursuant to sec. 278 (3), 118a (1), sentence 2 no. 8 AktG
2. Applicable issuer deadline	on February 4, 2025 from the beginning of the Annual General Meeting until the closing of the Annual General Meeting by the chairman of the meeting

	Specification in accordance with Implementing Regulation (EU): 20250204 from the beginning of the Annual General Meeting until the closing of the Annual General Meeting by the chairman of the meeting
--	---